Oxford Covid-19 vaccine tech maker Vaccitech targets $613 mn valuation in US IPOThe company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raise...
Oxford, AstraZeneca COVID-19 vaccine trials resume days after pauseThe study had been previously stopped in July for several days after a participant who got the vaccine developed neurological symptoms; it ...
How common cold viruses are being used in vaccines from Russia, ChinaSome researchers believe the strong immune response that caused problems with gene therapy makes these vectors well suited to vaccines, whe...